Evidence map›Paper›PMID 37113584›Full record

ArticleJournal of the anus, rectum and colon2023

Investigating the Follow-up Period after ALTA Sclerotherapy Using Transanal Ultrasonography.

Takenori Hada, Hidekazu Sugita, Fuminori Yoshida, Ayaka Fukuchi, Ayaka Ohzono, Shigemasa Sasaki, Michiaki Watanabe

Open access · goldAbstract read
In one paragraph

Article in Journal of the anus, rectum and colon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Takenori HadaOnaka Clinic, Oshiri Center, Tokyo, Japan.
Hidekazu SugitaDepartment of Clinical laboratory, Atsugi City Hospital, Atsugi, Japan.
Fuminori YoshidaDepartment of Clinical laboratory, Atsugi City Hospital, Atsugi, Japan.
Ayaka FukuchiDepartment of Clinical laboratory, Atsugi City Hospital, Atsugi, Japan.
Ayaka OhzonoDepartment of Clinical laboratory, Atsugi City Hospital, Atsugi, Japan.
Shigemasa SasakiDepartment of Surgery, Atsugi City Hospital, Atsugi, Japan.
Michiaki WatanabeDepartment of Surgery, Atsugi City Hospital, Atsugi, Japan.
City Hospital · GBHanda City Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aims to clarify the appropriate follow-up period after aluminum potassium sulfate and tannic acid (ALTA) sclerotherapy for internal hemorrhoids by transanal ultrasonography. Methods: Forty-four patients (98 lesions) who underwent ALTA sclerotherapy were analyzed. Transanal ultrasonography was performed pre and post-ALTA sclerotherapy to observe the thickness and the internal echo image of hemorrhoid tissue. Patients who developed complications were excluded. Results: No recurrence in 12 months was observed in 44 patients. After 1-3 months of ALTA sclerotherapy, hemorrhoids were observed in the low-echo imaging region. During this period, hemorrhoidal tissue was observed thickest by granulation. Moreover, hemorrhoid tissue contracted by fibrosis formed 5-7 months post-ALTA sclerotherapy, with a thinner hemorrhoid. Furthermore, hemorrhoids hardened and regressed with intense fibrosis 12-months after the therapy and eventually became thinner than pre-ALTA sclerotherapy. Conclusions: After ALTA sclerotherapy, the suggested follow-up period with and without the development of complications is ~6 and ~3 months, respectively.

Indexed as

ALTAfollow-up periodhemorrhoidsclerotherapytransanal ultrasonography

Identifiers

PMID37113584
PMCPMC10129361
OpenAlexW4366815546

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.